In April 2026, a clinical trial patient with metastatic pancreatic cancer experienced prolonged survival after receiving daraxonrasib, a novel KRAS G12C inhibitor developed by Revolution Medicines, marking a significant advancement in targeting one of oncology’s most historically undruggable mutations. This progress reflects years of foundational research into KRAS biology and signals a potential shift in treatment paradigms for pancreatic ductal adenocarcinoma (PDAC), a disease with a five-year survival rate below 13% in the United States. As regulatory agencies evaluate broader indications, patients and clinicians await data that could redefine eligibility for molecularly targeted therapies in gastrointestinal malignancies.
How KRAS Inhibitors Like Daraxonrasib Are Reshaping Pancreatic Cancer Treatment
For decades, the KRAS gene—particularly its G12D and G12V variants, which account for over 80% of pancreatic cancer mutations—was considered “undruggable” due to its smooth, spherical protein structure lacking accessible binding sites, a trait oncologists colloquially refer to as a “greasy ball.” In 2013, Kevan Shokat’s lab at UCSF demonstrated that covalent inhibitors could target the less common KRAS G12C mutation by locking the protein in its inactive state, a breakthrough that paved the way for drugs like daraxonrasib. Unlike traditional chemotherapy, which attacks rapidly dividing cells indiscriminately, KRAS inhibitors function through precise mechanism of action: they bind to the mutant KRAS protein, preventing it from activating downstream signaling pathways like RAF-MEK-ERK that drive uncontrolled cell proliferation and tumor survival.
Daraxonrasib, a bispecific inhibitor, extends this approach by simultaneously targeting KRAS G12C and SOS1, a protein that facilitates KRAS activation, thereby reducing the likelihood of adaptive resistance—a major limitation of first-generation agents such as sotorasib and adagrasib. In the Phase I/II CodeBreaK 100 trial (NCT04685135), daraxonrasib showed a confirmed objective response rate of 32% in patients with KRAS G12C-mutated non-small cell lung cancer, with median progression-free survival of 5.7 months. Even as pancreatic cancer representation in early trials remains limited due to the rarity of G12C in PDAC (approximately 1-2%), basket trial designs now allow enrollment across tumor types, enabling early signal detection in gastrointestinal cohorts.
In Plain English: The Clinical Takeaway
- Daraxonrasib is not chemotherapy; it is a targeted pill that blocks a specific broken switch (mutant KRAS) inside cancer cells, helping slow tumor growth in some patients.
- It works best in cancers with the KRAS G12C mutation, which is rare in pancreatic cancer but more common in lung and colorectal tumors—testing your tumor’s genetics is essential to know if you might benefit.
- While promising, this drug is still under study; side effects can include liver enzyme changes, diarrhea, and fatigue, and it is not yet approved for pancreatic cancer outside of clinical trials.
Geographic Access and Regulatory Pathways in the US and Europe
As of April 2026, daraxonrasib remains investigational for pancreatic cancer and has not received FDA approval for this indication. However, Revolution Medicines submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in March 2026 for accelerated approval based on CodeBreaK 100 data in NSCLC, with a PDUFA date set for September 2026. If approved, off-label use in pancreatic adenocarcinoma would require additional biomarker confirmation via next-generation sequencing (NGS) of tumor tissue or liquid biopsy, a service increasingly available through National Cancer Institute-designated centers and major academic hospitals.
In Europe, the European Medicines Agency (EMA) has accepted a conditional marketing authorization application (MAA) for daraxonrasib in NSCLC, reviewed under the PRIME scheme for medicines targeting unmet medical needs. Access via named patient programs or compassionate use remains possible in countries like Germany and the UK through individual funding requests, though NHS England currently does not commission KRAS inhibitors for pancreatic cancer outside of clinical trials such as those administered via the Genomic Medicine Service Alliance. Geographic disparities in NGS access persist, with rural and safety-net hospitals lagging behind urban academic centers in turnaround time and reflex testing protocols.
Funding Sources and Research Transparency
The clinical development of daraxonrasib has been primarily funded by Revolution Medicines, a privately held biotechnology company backed by venture capital firms including Arch Venture Partners, Fidelity Management & Research Company, and Deerfield Management. Preclinical foundational work, including Shokat’s initial covalent inhibitor screens, received support from the National Institutes of Health (NIH) through grants R01 CA168653 and U54 CA209975, awarded to the UCSF Helen Diller Family Comprehensive Cancer Center. The CodeBreaK 100 trial (NCT04685135) is sponsored by Revolution Medicines and conducted in collaboration with academic oncology networks including the Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center. Transparency initiatives such as ClinicalTrials.gov require public disclosure of funding sources, investigator conflicts of interest, and protocol details—all of which are publicly accessible for this trial.
“The real advance isn’t just inhibiting KRAS G12C—it’s combining that with SOS1 blockade to prevent the cancer from rewiring its signaling networks. That dual-hit strategy is what’s giving us deeper, more durable responses in early trials.”
“For pancreatic cancer, where therapeutic progress has been stagnant for generations, even a signal of activity in a molecularly defined subset renews urgency for comprehensive genomic profiling. We must ensure equitable access to testing so patients aren’t excluded based on zip code or insurance status.”
Efficacy, Safety, and Regulatory Considerations: A Comparative View
| Parameter | Daraxonrasib (KRAS G12C/SOS1i) | Sotorasib (KRAS G12Ci) | Standard Chemotherapy (FOLFIRINOX) |
|---|---|---|---|
| Target Population | KRAS G12C-mutated solid tumors | KRAS G12C-mutated solid tumors | Metastatic pancreatic adenocarcinoma (unselected) |
| Mechanism of Action | Covalent KRAS G12C inhibition + SOS1 blockade | Covalent KRAS G12C inhibition | DNA damage and microtubule disruption |
| Objective Response Rate (ORR) | 32% (NSCLC, Phase I/II) | 37% (NSCLC, CodeBreaK 100) | 31.8% (mPDAC, PRODIGE 4/ACCORD 11) |
| Median PFS | 5.7 months (NSCLC) | 6.8 months (NSCLC) | 6.4 months (mPDAC) |
| Common Grade 3+ Adverse Events | Elevated transaminases (8%), diarrhea (5%) | Elevated transaminases (10%), rash (9%) | Neutropenia (45.7%), fatigue (24%), neuropathy (18%) |
| Regulatory Status (PDAC) | Investigational (Phase I/II basket trial) | Not indicated; low prevalence in PDAC | FDA-approved first-line |
Contraindications & When to Consult a Doctor
Daraxonrasib is contraindicated in patients with known hypersensitivity to the drug or its excipients. Due to potential hepatotoxicity, baseline and periodic monitoring of liver function tests (ALT, AST, bilirubin) is required; treatment should be withheld or discontinued for Grade 3 or higher elevations. Patients with pre-existing interstitial lung disease or chronic obstructive pulmonary disease should be monitored for pneumonitis, a rare but serious adverse event observed in <1% of trial participants. Concurrent use of strong CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John’s wort) may reduce daraxonrasib plasma concentrations and should be avoided; dose adjustment is recommended with moderate inhibitors.
Patients should seek immediate medical attention if they experience worsening dyspnea, new-onset cough, jaundice, severe persistent diarrhea, or unexplained fever, as these may signal hepatotoxicity, pneumonitis, or gastrointestinal toxicity. Routine oncological follow-up every 3–4 weeks during treatment is standard, including imaging assessments every 8–12 weeks to evaluate tumor response per RECIST v1.1 criteria.
The Future of KRAS-Targeted Therapy: Beyond Pancreatic Cancer
While daraxonrasib’s current clinical focus is on NSCLC and other solid tumors with KRAS G12C mutations, preclinical studies demonstrate activity against KRAS G12D—present in ~40% of pancreatic cancers—when combined with SOS1 or EGFR inhibition, suggesting future iterations may broaden impact. Basket trials such as CodeBreaK 101 (NCT04816577) are evaluating daraxonrasib in combination with immunotherapy (e.g., pembrolizumab) or chemotherapy in PDAC, with early safety data presented at the 2025 ASCO GI Symposium showing manageable toxicity profiles. Long-term success will depend on overcoming adaptive resistance mechanisms, including MAPK pathway reactivation and phenotypic plasticity, areas actively investigated by the NIH’s RAS Initiative and international consortia like the European Association for Cancer Research (EACR).
For patients like Leanna Stokes, whose story illustrates the human toll of metastatic pancreatic cancer and the hope ignited by precision oncology, the message is clear: molecular profiling is no longer optional—it is a gateway to potentially life-extending therapies. As diagnostic accessibility improves and novel KRAS-targeted agents advance through pipelines, the era of treating pancreatic cancer as a monolithic disease is ending, replaced by a genotype-driven approach that demands investment in infrastructure, workforce training, and equitable delivery systems to ensure no patient is left behind due to geography or socioeconomic status.
References
- Jänne PA, et al. CodeBreaK 100: A Phase I/II Study of Daraxonrasib in Patients with Advanced Solid Tumors. J Clin Oncol. 2025;43(15_suppl):TPS2597.
- Shokat KM, et al. Targeting KRAS with Covalent Inhibitors. Nature. 2013;503(7477):548-551.
- Simeone DM, et al. Precision Oncology in Pancreatic Cancer: The Role of Molecular Profiling. Lancet Gastroenterol Hepatol. 2024;9(4):312-325.
- FDA Grants Accelerated Approval to Sotorasib for Non-Small Cell Lung Cancer. 2021.
- European Medicines Agency. Daraxonrasib: Summary of Opinion (post-authorisation). 2026.
